1 - 25 of 64 results for author:"Koster J." in Literature citations
Results Customize
› Repeat search in UniProtKB (38)
| Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Valentijn L.J., Koster J., Haneveld F., Aissa R.A., van Sluis P., Broekmans M.E., Molenaar J.J., van Nes J., Versteeg R. Proc. Natl. Acad. Sci. U.S.A. 109:19190-19195(2012) · Mapped (7) |
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Sturm D., Witt H., Hovestadt V., Khuong-Quang D.A., Jones D.T., Konermann C., Pfaff E., Tonjes M., Sill M., Bender S. et al. Cancer Cell 22:425-437(2012) · Mapped (12) |
| Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. von Bueren A.O., Bacolod M.D., Hagel C., Heinimann K., Fedier A., Kordes U., Pietsch T., Koster J., Grotzer M.A., Friedman H.S. et al. Br. J. Cancer 107:1399-1408(2012) · Mapped (3) |
| Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Schramm A., Koster J., Marschall T., Martin M., Schwermer M., Fielitz K., Buchel G., Barann M., Esser D., Rosenstiel P. et al. Int. J. Cancer 132:E106-15(2013) · Mapped (12) |
| The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. Munoz J., Stange D.E., Schepers A.G., van de Wetering M., Koo B.K., Itzkovitz S., Volckmann R., Kung K.S., Koster J., Radulescu S. et al. EMBO J. 31:3079-3091(2012) · Mapped (4) |
| A novel defect of peroxisome division due to a homozygous non-sense mutation in the PEX11beta gene. Ebberink M.S., Koster J., Visser G., Spronsen F.v., Stolte-Dijkstra I., Smit G.P., Fock J.M., Kemp S., Wanders R.J., Waterham H.R. J. Med. Genet. 49:307-313(2012) · UniProtKB (1) · Mapped (2) |
| Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Kemper K., Versloot M., Cameron K., Colak S., de Sousa e Melo F., de Jong J.H., Bleackley J., Vermeulen L., Versteeg R., Koster J. et al. Clin. Cancer Res. 18:3132-3141(2012) · Mapped (4) |
| Xenobiotic- and jasmonic acid-inducible signal transduction pathways have become interdependent at the Arabidopsis CYP81D11 promoter. Koster J., Thurow C., Kruse K., Meier A., Iven T., Feussner I., Gatz C. Plant Physiol. 159:391-402(2012) · Mapped (1) |
| Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. Lamers F., Schild L., den Hartog I.J., Ebus M.E., Westerhout E.M., Ora I., Koster J., Versteeg R., Caron H.N., Molenaar J.J. Eur. J. Cancer 48:3093-3103(2012) · Mapped (4) |
| Clonal selection drives genetic divergence of metastatic medulloblastoma. Wu X., Northcott P.A., Dubuc A., Dupuy A.J., Shih D.J., Witt H., Croul S., Bouffet E., Fults D.W., Eberhart C.G. et al. Nature 482:529-533(2012) · Mapped (20) |
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Rausch T., Jones D.T., Zapatka M., Stutz A.M., Zichner T., Weischenfeldt J., Jager N., Remke M., Shih D., Northcott P.A. et al. Cell 148:59-71(2012) · Mapped (32) |
| PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W. Int. J. Cancer 131:1556-1568(2012) · Mapped (7) |
| Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma. Bunt J., Hasselt N.E., Zwijnenburg D.A., Koster J., Versteeg R., Kool M. PLoS ONE 6:e26058-e26058(2011) · Mapped (11) |
| OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. Bunt J., Hasselt N.E., Zwijnenburg D.A., Hamdi M., Koster J., Versteeg R., Kool M. Int. J. Cancer 131:E21-32(2012) · Mapped (4) |
| Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Santo E.E., Ebus M.E., Koster J., Schulte J.H., Lakeman A., van Sluis P., Vermeulen J., Gisselsson D., Ora I., Lindner S. et al. Oncogene 31:1571-1581(2012) · Mapped (2) |
| Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines. Bunt J., de Haas T.G., Hasselt N.E., Zwijnenburg D.A., Koster J., Versteeg R., Kool M. Mol. Cancer Res. 8:1344-1357(2010) · Mapped (4) |
| Congenital hyperinsulinism and glucose hypersensitivity in homozygous and heterozygous carriers of Kir6.2 (KCNJ11) mutation V290M mutation: K(ATP) channel inactivation mechanism and clinical management. Loechner K.J., Akrouh A., Kurata H.T., Dionisi-Vici C., Maiorana A., Pizzoferro M., Rufini V., de Ville de Goyet J., Colombo C., Barbetti F. et al. Diabetes 60:209-217(2011) · Mapped (3) |
| Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. Vyas A.K., Koster J.C., Tzekov A., Hruz P.W. J. Biol. Chem. 285:36395-36400(2010) · Mapped (6) |
| NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., Nijkamp W., Xie J., Callens T., Asgharzadeh S. et al. Cell 142:218-229(2010) · Mapped (10) |
| The ATP-sensitive K(+)-channel (K(ATP)) controls early left-right patterning in Xenopus and chick embryos. Aw S., Koster J.C., Pearson W., Nichols C.G., Shi N.Q., Carneiro K., Levin M. Dev. Biol. 346:39-53(2010) · UniProtKB (1) |
| Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. Verissimo C.S., Molenaar J.J., Meerman J., Puigvert J.C., Lamers F., Koster J., Danen E.H., van de Water B., Versteeg R., Fitzsimons C.P. et al. Endocr. Relat. Cancer 17:399-414(2010) · Mapped (4) |
| Small intestinal mucosa expression of putative chaperone fls485. Reinartz A., Ehling J., Franz S., Simon V., Bravo I.G., Tessmer C., Zentgraf H., Lyer S., Schneider U., Koster J. et al. BMC Gastroenterol. 10:27-27(2010) · UniProtKB (1) · Mapped (2) |
| Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Molenaar J.J., Ebus M.E., Koster J., Santo E., Geerts D., Versteeg R., Caron H.N. Oncogene 29:2739-2745(2010) · Mapped (7) |
| The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Geerts D., Koster J., Albert D., Koomoa D.L., Feith D.J., Pegg A.E., Volckmann R., Caron H., Versteeg R., Bachmann A.S. Int. J. Cancer 126:2012-2024(2010) · Mapped (5) |
| K(ATP) channelopathies in the pancreas. Remedi M.S., Koster J.C. Pflugers Arch. 460:307-320(2010) · Mapped (3) |